Codexis, Inc. (NASDAQ:CDXS) Shares Acquired by abrdn plc

abrdn plc lifted its position in Codexis, Inc. (NASDAQ:CDXS) by 62.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 800,410 shares of the biotechnology company’s stock after acquiring an additional 307,762 shares during the period. abrdn plc’s holdings in Codexis were worth $2,465,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently modified their holdings of CDXS. Private Advisor Group LLC boosted its holdings in Codexis by 1.3% in the third quarter. Private Advisor Group LLC now owns 278,699 shares of the biotechnology company’s stock valued at $858,000 after purchasing an additional 3,458 shares during the last quarter. Rhumbline Advisers raised its position in Codexis by 3.8% during the second quarter. Rhumbline Advisers now owns 108,594 shares of the biotechnology company’s stock worth $337,000 after acquiring an additional 4,017 shares during the period. Algert Global LLC lifted its stake in Codexis by 17.1% in the 2nd quarter. Algert Global LLC now owns 41,556 shares of the biotechnology company’s stock valued at $129,000 after buying an additional 6,069 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its stake in shares of Codexis by 57.4% in the first quarter. State Board of Administration of Florida Retirement System now owns 28,500 shares of the biotechnology company’s stock worth $99,000 after acquiring an additional 10,395 shares during the last quarter. Finally, SG Americas Securities LLC grew its holdings in shares of Codexis by 72.6% during the second quarter. SG Americas Securities LLC now owns 36,677 shares of the biotechnology company’s stock worth $114,000 after buying an additional 15,425 shares in the last quarter. 78.54% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, major shareholder Opaleye Management Inc. purchased 1,055,000 shares of the company’s stock in a transaction that occurred on Friday, September 20th. The shares were purchased at an average price of $3.01 per share, for a total transaction of $3,175,550.00. Following the purchase, the insider now directly owns 8,390,000 shares of the company’s stock, valued at $25,253,900. This represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders have purchased 1,166,000 shares of company stock valued at $3,514,910. 2.10% of the stock is owned by corporate insiders.

Codexis Stock Down 0.3 %

Shares of NASDAQ CDXS opened at $3.49 on Tuesday. Codexis, Inc. has a 12-month low of $1.51 and a 12-month high of $4.91. The stock has a market cap of $247.55 million, a P/E ratio of -4.01 and a beta of 2.07. The company has a current ratio of 2.99, a quick ratio of 2.92 and a debt-to-equity ratio of 0.46. The business’s fifty day simple moving average is $3.05 and its 200-day simple moving average is $3.16.

Codexis (NASDAQ:CDXS) last announced its quarterly earnings data on Thursday, October 31st. The biotechnology company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.04). The firm had revenue of $12.83 million during the quarter, compared to analysts’ expectations of $11.64 million. Codexis had a negative net margin of 96.35% and a negative return on equity of 71.00%. During the same period in the prior year, the company posted ($0.26) earnings per share. As a group, equities analysts predict that Codexis, Inc. will post -0.75 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on CDXS. Benchmark reaffirmed a “hold” rating on shares of Codexis in a report on Monday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $11.00 price objective on shares of Codexis in a research report on Friday, September 20th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, Codexis has an average rating of “Hold” and an average price target of $8.75.

Codexis Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.